While therapies that harness the power of the immune system against cancer have made remarkable progress against certain types of tumours, they still remain ineffective in most cancer patients.
A new study has described a method of reprogramming the regulatory T cells that usually suppress immune responses into inflammatory cells that not only permit but also intensify an anti-tumour immune response.
Details of this study have been published in the journal Nature.
“Many patients’ tumours do not respond to immune therapies – such as immune checkpoint blockade – because of a lack of pre-existing inflammation that is required for those therapies to work,” said Thorsten Mempel, MD, PhD, of the MGH CIID, senior author of this study. “Our study shows that reprogrammed Treg cells provide exactly the type of inflammation that is lacking. Indeed, we found in mice that reprogramming tumour-infiltrating Treg cells to secrete inflammatory cytokines makes previously unresponsive tumours highly sensitive to PD-1 blockade.”
The MGH study focused on the CBM complex – a large protein cluster within immune cells that helps regulate their activation, proliferation and function.
Recent research has revealed a critical role for the CBM complex in lymphocyte function, and since deleting one of three key proteins, called CARMA1, is already known to reduce the function of effector T cells, the team examined the effects of CARMA1 deletion on Treg cells. Their experiments revealed that targeting the CBM complex – either by deleting one or both copies of the CARMA1 gene in Treg cells or by treating tumour-bearing mice with a drug that inhibits MALT1, another component of the complex – caused Treg cells to secrete the immunostimulatory cytokine interferon gamma in tumour tissue alone.
The ability to selectively modulate the function of Treg in tumours can avoid the risk of autoimmune disease that would result from systemic Treg depletion.
CBM targeting led to inflammation of tumour tissue and increased infiltration by cytotoxic CD8 T cells and natural killer cells.
But it only reduced the rate of tumour growth in mouse models of melanoma and colon cancer because the activity of those immune cells was still limited by the immune checkpoint protein PD-1.
However, blocking the activity of PD-1 with antibodies led to elimination of tumours that had been inflamed by anti-CBM treatment.
“Treg cells are preferentially ‘auto-reactive,’ meaning they react to our own, ‘self’ tissue antigens,” explained Mempel, an associate professor of Medicine at Harvard Medical School. “By reprogramming Treg cells in tumour tissue, we create a local inflammatory autoimmune reaction that primes tumours for immune therapies. So instead of trying to get rid of Treg cells, we now can use them as an asset, harnessing their self-reactivity for cancer treatment.”
Mauro Di Pilato, PhD, a research fellow in Dr. Mempel’s lab and lead author of the study, added: “Now we need to assess whether this approach works as well in humans as it does in mice and understand why Treg cells in the tumour environment, but not elsewhere, are reprogrammed through targeting of the CBM complex. The ability to reprogram Treg cells to improve patient response to immune checkpoint blockade has the potential of increasing the number of patients who can be helped with that approach.”
Source: Massachusetts General Hospital